Please provide your email address to receive an email when new articles are posted on . Both drugs showed safety and efficacy at 3 and 6 months. Ustekinumab achieved significantly longer treatment ...

In a propensity score-matched analysis including 754 patients ages 50 and up, use of vedolizumab was associated with a 45.4% risk of treatment failure -- defined as a composite risk of IBD-related ...

CHARLOTTE, N.C. — Exposure to ustekinumab and vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with ...

Ustekinumab (Stelara, Janssen) appears superior to vedolizumab (Entyvio, Takeda) on multiple measures of response and remission among patients with Crohn's disease who failed at least one anti-TNF ...